Galera Therapeutics amends Series B Preferred terms to allow board discretion to convert to common stock

Galera Therapeutics, Inc.

On Feb 12, 2026, Galera filed a Certificate of Amendment to its Series B Preferred Certificate of Designation.
Amendment grants the board sole discretion to convert Series B Preferred into common stock using the Conversion Ratio.
Amendment was approved by the board and by unanimous written consent of Series B holders.
No immediate conversion; board may elect to convert in whole or in part at a later date.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Galera Therapeutics, Inc.: Amended Series B Preferred Stock Certificate of Designation to allow board discretion to convert shares to Common Stock based on Conversion Ratio (effective 2026-02-12).

Change: charter amendment
Effective: 2026-02-12

Exact text from the filing

On February 12, 2026, Galera Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of Delaware.

View on SEC.gov

40 governance changes filed in the last 30 days. Browse all governance changes →

Galera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-055919

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.